Fanconi syndrome due to deferasirox
- PMID: 19493602
- DOI: 10.1053/j.ajkd.2009.03.013
Fanconi syndrome due to deferasirox
Abstract
Deferasirox is an innovative iron-chelating treatment. However, preliminary data have suggested that kidney toxicity may be a major issue in the management of patients receiving this drug. We report a case of Fanconi syndrome associated with acute renal insufficiency in a patient receiving deferasirox. The latter has to be added to the expanding list of drugs that may induce Fanconi syndrome. Careful monitoring of kidney function and markers of proximal tubular injury are mandatory in patients undergoing treatment with deferasirox.
Comment in
-
Charge states of deferasirox-ferric iron complexes.Am J Kidney Dis. 2010 Mar;55(3):614-5. doi: 10.1053/j.ajkd.2009.10.065. Am J Kidney Dis. 2010. PMID: 20189051 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources